The leader in pharma sales, Pfizer is well known thanks to several household name drugs, including Lipitor, Advil, Celebrex, Zithromax and the ever-abundant "little blue pill," Viagra. As the company looks at the looming Lipitor patent cliff, CEO Ian Read has been searching for new methods to keep revenue high, other than new approved drugs. Recently, the company has been considering spinning off portions of the company to create smaller, more profitable arms, a polar opposite of former CEO Jeffrey Kindler's bulk-up strategy of years past. The company's past purchases and mergers have included King Pharmaceuticals, Warner-Lambert, SUGEN and a $68 billion purchase, Wyeth, in 2009.

Wyeth provided Pfizer with an influx of 17 new drugs and vaccines, including Enbrel, Effexor, Prevnar and Pristiq, and Pfizer declared the merger made them "one of the most diversified companies in the global health care industry." And the company continues to move forward as it focuses on hot areas, including Alzheimer's, oncology and vaccines.

The company's legal woes have caused headaches as well. Pfizer has paid over $340 million in settlements for its menopause treatment, Prempro and has 1,200 cases pending for the anti-smoking drug Chantix. Back in 2009, it paid $1.3 billion for illegal marketing fines for the painkiller Bextra, making it the largest fine in United States history.

Pfizer has stayed in the top two on FiercePharma's annual layoffs list for the past three years, thanks in part to the company's 2009 megamerger with Wyeth, and the pressure could be felt for another five years. The company also placed second in the Top 15 R&D Budgets, with $7.4 billion in 2009. But those numbers will continue to slip as Pfizer looks towards development deals instead of in-house research.



Latest Headlines

Latest Headlines

As patent cliff nears, more lawsuits filed

Patent lawsuits are all in a day's work for Big Pharma, yes? Hardly a day goes by that some drugmaker doesn't sue a generics firm in an attempt to keep copycat meds off the market. Especially now,

Germans accuse Pfizer of sitting on data

German regulators aren't too happy with Pfizer. The country's Institute for Quality and Efficacy in Health Care (IQWiG) is accusing the drugmaker of deliberately withholding data on its

Ex-Pfizer scientists, university partner on drug program

Wayne State University has teamed up with an innovative company created by a group of former Pfizer scientists to advance a new therapy discovered in one of its academic labs into clinical

Pfizer on lookout for Middle East deals

Pfizer sees big growth in the Middle East. The region "is becoming one of our key emerging markets," Pfizer's emerging markets chief Jean-Michel Halfon told Bloomberg. "this is a market where we

Pfizer revving up for generics growth

Pfizer is actively scouting for deals to expand its generics business. David Simmons, president of Pfizer's new "established products" unit, told the Goldman Sachs Healthcare Conference that the

Pfizer's oral RA drug passes mid-stage test

Pfizer is claiming success in a mid-stage trial of an experimental oral drug for rheumatoid arthritis, saying the data has helped it hone in on the doses that will be tested in an upcoming Phase III

Pfizer's new cancer drug for dogs wins approval

Pfizer has won approval for a new cancer drug for dogs with the kind of clinical data most developers can only dream about. The FDA approved Palladia to treat advanced mast cell tumors in dogs, the

Pfizer halts Sutent breast-cancer trial

Typically, Big Pharma doesn't wait till after the markets close to announce news unless that news isn't so welcome--and yesterday's after-four o'clock release was no exception. Pfizer decided to pull

For Sale: Two Pfizer jets for $65M

Looking for a bargain on a corporate jet? Pfizer is scouting for buyers for two of its Gulfstream aircraft, a Gulfstream V model and a Gulfstream 550. The drugmaker just cut its asking prices as

Pfizer eyes troubled Intercytex for buyout

Despite setbacks, Intercytex is working hard to stay in the game. The troubled U.K. biotech saw it shares jump 30 percent today on the news that Pfizer is among the company's suitors. The interest